Costin Tomescu1, Pablo Tebas2, Luis J Montaner1. 1. HIV Immunopathogenesis Laboratory, The Wistar Institute 2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
DESIGN: We have previously shown that IFN-α stimulation augments direct natural killer (NK) cell lysis of autologous CD4 primary T cells infected with certain HIV-1 isolates based upon major histocompatibility complex class 1 (MHC-1) downregulation capacity. Here, we investigated if antibody-dependent cellular cytotoxicity (ADCC) could trigger lysis of HIV-1 isolates that were resistant to direct NK lysis and if IFN-α prestimulation of NK cells could further enhance ADCC. METHODS: Using broadly neutralizing monoclonal antibodies against gp120 (VRC01 or PGV04) or plasma from HIV-1-infected patients (ART-suppressed or elite controller) to trigger ADCC, we measured NK cell chromium release cytotoxicity against HIV-1-infected autologous CD4 primary T cells and NK cell CD107a degranulation against gp120-coated CD4 T cells. Total or NK-depleted peripheral blood mononuclear cells were used as effectors in the presence or absence of IFN-α prestimulation. RESULTS: Plasma from HIV-1-infected patients and monoclonal antibodies against gp120 could trigger NK-dependent ADCC lysis of viral isolates that were resistant to direct NK cell lysis following IFN-α stimulation. In contrast, viral isolates that exhibited potent MHC-I downregulation capacity could be lysed by NK cells through either IFN-α stimulated direct cytotoxicity or through ADCC. When utilized in combination, IFN-α prestimulation significantly augmented ADCC lysis of HIV-1-infected target cells and increased NK cell CD107a degranulation against gp120-coated ADCC targets (P < 0.05, n = 6). CONCLUSION: HIV-1 isolates with lower MHC-I downregulation capacity are resistant to direct lysis following IFN-α stimulation but retain sensitivity to ADCC. IFN-α prestimulation can significantly increase NK-mediated clearance of HIV-1-infected target cells by both ADCC and/or direct cytotoxicity depending on MHC downregulation status.
DESIGN: We have previously shown that IFN-α stimulation augments direct natural killer (NK) cell lysis of autologous CD4 primary T cells infected with certain HIV-1 isolates based upon major histocompatibility complex class 1 (MHC-1) downregulation capacity. Here, we investigated if antibody-dependent cellular cytotoxicity (ADCC) could trigger lysis of HIV-1 isolates that were resistant to direct NK lysis and if IFN-α prestimulation of NK cells could further enhance ADCC. METHODS: Using broadly neutralizing monoclonal antibodies against gp120 (VRC01 or PGV04) or plasma from HIV-1-infectedpatients (ART-suppressed or elite controller) to trigger ADCC, we measured NK cell chromium release cytotoxicity against HIV-1-infected autologous CD4 primary T cells and NK cell CD107a degranulation against gp120-coated CD4 T cells. Total or NK-depleted peripheral blood mononuclear cells were used as effectors in the presence or absence of IFN-α prestimulation. RESULTS: Plasma from HIV-1-infectedpatients and monoclonal antibodies against gp120 could trigger NK-dependent ADCC lysis of viral isolates that were resistant to direct NK cell lysis following IFN-α stimulation. In contrast, viral isolates that exhibited potent MHC-I downregulation capacity could be lysed by NK cells through either IFN-α stimulated direct cytotoxicity or through ADCC. When utilized in combination, IFN-α prestimulation significantly augmented ADCC lysis of HIV-1-infected target cells and increased NK cell CD107a degranulation against gp120-coated ADCC targets (P < 0.05, n = 6). CONCLUSION:HIV-1 isolates with lower MHC-I downregulation capacity are resistant to direct lysis following IFN-α stimulation but retain sensitivity to ADCC. IFN-α prestimulation can significantly increase NK-mediated clearance of HIV-1-infected target cells by both ADCC and/or direct cytotoxicity depending on MHC downregulation status.
Authors: Costin Tomescu; Fuh-Mei Duh; Rebecca Hoh; Anne Viviani; Kara Harvill; Maureen P Martin; Mary Carrington; Steven G Deeks; Luis J Montaner Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: E O Long; D N Burshtyn; W P Clark; M Peruzzi; S Rajagopalan; S Rojo; N Wagtmann; C C Winter Journal: Immunol Rev Date: 1997-02 Impact factor: 12.988
Authors: A López-Vázquez; A Miña-Blanco; J Martínez-Borra; P D Njobvu; B Suárez-Alvarez; M A Blanco-Gelaz; S González; L Rodrigo; C López-Larrea Journal: Hum Immunol Date: 2005-03 Impact factor: 2.850
Authors: Livio Azzoni; Andrea S Foulkes; Emmanouil Papasavvas; Angela M Mexas; Kenneth M Lynn; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Ian Frank; Michael P Busch; Steven G Deeks; Mary Carrington; Una O'Doherty; Jay Kostman; Luis J Montaner Journal: J Infect Dis Date: 2012-10-26 Impact factor: 5.226
Authors: Pascale André; Roberta Castriconi; Marion Espéli; Nicolas Anfossi; Tiffany Juarez; Sophie Hue; Holli Conway; François Romagné; Alessandra Dondero; Marina Nanni; Sophie Caillat-Zucman; David H Raulet; Cristina Bottino; Eric Vivier; Alessandro Moretta; Pascale Paul Journal: Eur J Immunol Date: 2004-04 Impact factor: 5.532
Authors: Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen Journal: EBioMedicine Date: 2020-08-19 Impact factor: 8.143
Authors: Emmanouil Papasavvas; Livio Azzoni; Andrew V Kossenkov; Noor Dawany; Knashawn H Morales; Matthew Fair; Brian N Ross; Kenneth Lynn; Agnieszka Mackiewicz; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Jay R Kostman; Louise Showe; Luis J Montaner Journal: J Immunol Date: 2019-06-28 Impact factor: 5.422
Authors: Costin Tomescu; Kyle Kroll; Krystal Colon; Emmanouil Papasavvas; Ian Frank; Pablo Tebas; Karam Mounzer; Roger Keith Reeves; Luis J Montaner Journal: Eur J Immunol Date: 2021-06-19 Impact factor: 6.688